Gastro hep advances最新文献

{"title":"Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content","authors":"Haoxiang Zhu ,&nbsp;Ling Xu ,&nbsp;Yinhua Lv ,&nbsp;Juan Yang ,&nbsp;Jihan Huang ,&nbsp;Qingshan Zheng ,&nbsp;Guang Ji ,&nbsp;Lujin Li","doi":"10.1016/j.gastha.2024.100593","DOIUrl":"10.1016/j.gastha.2024.100593","url":null,"abstract":"<div><h3>Background and Aims</h3><div>This study aims to conduct a comprehensive quantitative analysis of various nonalcoholic fatty liver disease (NAFLD) therapeutics, utilizing magnetic resonance (MR)-detected liver fat content (LFC) as the efficacy endpoint, and to identify biomarkers correlated with changes in LFC based on published literature.</div></div><div><h3>Methods</h3><div>We performed a systematic search of public databases for placebo-controlled randomized trials on NAFLD up to September 29, 2023. A random-effects meta-analysis was employed to assess efficacy differences between drugs with various mechanisms and placebo. Initial Pearson correlation analysis explored the relationships between biomarkers and LFC. For biomarkers showing significant correlations with LFC, further modeling analysis was conducted to examine their relationship characteristics.</div></div><div><h3>Results</h3><div>Our analysis included 36 studies with 3222 subjects and 33 investigational drugs, which were categorized into 6 mechanistic groups. Drugs such as fibroblast growth factor agonists, and those targeting adipocytes, inflammation, or fibrosis, showed greater efficacy in reducing LFC compared to Resmetirom, which has an efficacy of reducing LFC by 5.2%. From the 121 biomarkers analyzed, alanine aminotransferase and aspartate aminotransferase demonstrated moderate correlations with LFC; specifically, changes of −5.9 U/L in alanine aminotransferase or −3.3 U/L in aspartate aminotransferase were associated with an additional 1% reduction in LFC.</div></div><div><h3>Conclusion</h3><div>The results of this study provide valuable insights for the clinical development of future NAFLD therapeutics, highlighting the efficacy of specific drug mechanisms and the potential of certain biomarkers as surrogate endpoints.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 4","pages":"Article 100593"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143377538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab Improves Histopathologic Features in Patients With Eosinophilic Esophagitis: LIBERTY EoE TREET Study Results","authors":"Margaret H. Collins ,&nbsp;Marc E. Rothenberg ,&nbsp;Evan S. Dellon ,&nbsp;Albert J. Bredenoord ,&nbsp;Ikuo Hirano ,&nbsp;John Leung ,&nbsp;Xian Sun ,&nbsp;Lila Glotfelty ,&nbsp;Arsalan Shabbir","doi":"10.1016/j.gastha.2025.100646","DOIUrl":"10.1016/j.gastha.2025.100646","url":null,"abstract":"<div><h3>Background and Aims</h3><div>This post hoc analysis assessed the effect of dupilumab on the individual components of the Eosinophilic Esophagitis Histology Scoring System (EoEHSS) and the relationship between histopathologic and endoscopic measures in the LIBERTY eosinophilic esophagitis (EoE) TREET population.</div></div><div><h3>Methods</h3><div>The analysis included patients who received dupilumab 300 mg weekly (qw) or placebo for 24 weeks (Parts A and B). Eligible patients who completed Parts A or B entered Part C and received dupilumab 300 mg qw for 28 weeks (week 52). Changes from baseline to week 24 and week 52 in the EoEHSS grade/stage components were assessed. Associations between histopathologic, symptomatic, and endoscopic features were evaluated using Spearman correlation.</div></div><div><h3>Results</h3><div>At week 24, dupilumab improved most EoEHSS grade/stage component scores vs placebo. These improvements were sustained at week 52 in patients continuously on dupilumab; patients who switched from placebo to dupilumab at week 24 improved EoEHSS grade/stage component scores at week 52 to levels similar to those observed in patients continuously on dupilumab. Dupilumab also increased the proportion of patients in remission at week 24 vs placebo, with further increases at week 52, as assessed by the EoE histology remission score. EoEHSS grade and stage total scores correlated strongly with peak eosinophil count (PEC), moderately to strongly with Endoscopic Reference Score, and weakly with Dysphagia Symptom Questionnaire score. Several EoEHSS grade/stage component scores correlated strongly with PEC but not with Dysphagia Symptom Questionnaire scores.</div></div><div><h3>Conclusion</h3><div>Dupilumab 300 mg qw improved histopathologic measures of EoE beyond PEC at week 24, with improvements sustained to week 52 (<span><span>Video 1</span></span>).</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 6","pages":"Article 100646"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unexpected Liver Hematoma After Endoscopic Submucosal Dissection for Duodenal Adenoma","authors":"Sachiyo Onishi,&nbsp;Masaya Kubota,&nbsp;Masahito Shimizu","doi":"10.1016/j.gastha.2025.100671","DOIUrl":"10.1016/j.gastha.2025.100671","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 7","pages":"Article 100671"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ulcerative Colitis but Not Dextran Sodium Sulfate–Induced Colitis–Associated Microbiota Promotes Early Biomarkers of Colitis in Interleukin-10 −/− Mice","authors":"Kayla Roy,&nbsp;Edward Moncada,&nbsp;Lavanya Reddivari","doi":"10.1016/j.gastha.2025.100636","DOIUrl":"10.1016/j.gastha.2025.100636","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis (UC), are inflammatory gastrointestinal conditions in which the pathogenesis is influenced by immune dysfunction, genetics, and environmental factors. Of the 2 conditions, UC is more prevalent, and there is a positive correlation between bacterial dysbiosis and colitis severity and incidence. Therefore, we hypothesize that mice that are genetically predisposed to colitis when colonized with colitic associated bacteria will exhibit an early onset of colitis biomarkers.</div></div><div><h3>Methods</h3><div>Four sets of germ-free interleukin-10 −/− mice were gavaged orally with pooled fecal samples from 2 healthy individuals or an individual with severe colitis or healthy mice or dextran sodium sulfate (DSS)–induced colitis mice. The disease activity index was used to rank colitis severity weekly in transplanted mice for eight weeks.</div></div><div><h3>Results</h3><div>There were significant differences in alpha (Shannon Index) and beta diversity (Bray-Curtis) between healthy and colitic-associated microbiota recipients, indicating dysbiosis (human fecal microbial transplantation <em>P</em> = 8.09∗10^-6, <em>P</em> = .001); (Mice fecal microbiota transplant <em>P</em> = .0197, <em>P</em> = .025). Despite the lack of colitis development, UC-associated microbiota recipients had reduced mucus thickness and increased expression of proinflammatory cytokines in the distal colon compared to healthy-associated microbiota recipients. However, DSS-induced colitis associated microbiota recipients did not show an increase in colitis biomarkers compared to healthy associated microbiota recipients.</div></div><div><h3>Conclusion</h3><div>This study demonstrates that UC-associated bacterial dysbiosis induces colonic inflammation and mucus thinning, biomarkers of early colitis onset, in interleukin-10 −/− mice compared to mice with healthy human associated bacteria.</div><div>Colitis induction depends on bacterial community stability as DSS-induced colitis associated microbiota recipients did not show an increase in colitis or colitis biomarkers in the absence of DSS.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 6","pages":"Article 100636"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143917641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparity in Access to Physicians With High Adenoma Detection Rates","authors":"Adedeji Adenusi ,&nbsp;Xucong Meng ,&nbsp;Mohammad Bilal ,&nbsp;Seth Gross ,&nbsp;Mark Pochapin ,&nbsp;Aasma Shaukat","doi":"10.1016/j.gastha.2025.100672","DOIUrl":"10.1016/j.gastha.2025.100672","url":null,"abstract":"","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 7","pages":"Article 100672"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ulcerative Colitis Preceding Asymptomatic Wilson’s Disease: A Case Report and Literature Review","authors":"Jun Kunizaki ,&nbsp;Yuko Yoto ,&nbsp;Yoshinobu Nagaoka ,&nbsp;Akira Ishii ,&nbsp;Tomoe Kazama ,&nbsp;Kohei Wagatsuma ,&nbsp;Noriyuki Akutsu ,&nbsp;Aki Ishikawa ,&nbsp;Toju Tanaka ,&nbsp;Shintaro Sugita ,&nbsp;Takeshi Tsugawa ,&nbsp;Hiroshi Nakase","doi":"10.1016/j.gastha.2024.09.003","DOIUrl":"10.1016/j.gastha.2024.09.003","url":null,"abstract":"<div><div>An 11-year-old girl with quiescent ulcerative colitis had sustained elevation of liver enzymes. Although she had no clinical symptoms suggestive of Wilson’s disease, such as Kayser–Fleischer rings, laboratory data showed decreased serum copper and ceruloplasmin levels and increased urinary copper excretion. Genetic testing showed pathogenic variants in <em>ATP7B</em> allele 1: c.2004_2006delGAT (p. Met668del) and allele 2: c.1708-5T&gt;G. After starting copper chelators, her liver function normalized, and she maintained clinical and endoscopic remission of ulcerative colitis. Mutations or defective functions of <em>ATP7B</em> lead to hepatic dysfunction and intestinal inflammation.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 1","pages":"Article 100548"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11714711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Endoscopic Retrograde Cholangiopancreatography for Management of Choledocholithiasis in a Patient With Situs Inversus Totalis: A Case Report and Literature Review","authors":"Bashayer Alrufayi ,&nbsp;Saad Almutairi ,&nbsp;Abbas Zagnoon","doi":"10.1016/j.gastha.2024.09.010","DOIUrl":"10.1016/j.gastha.2024.09.010","url":null,"abstract":"<div><div>Situs inversus totalis is a rare congenital disorder defined by the transposition of all viscera to the opposite side of the body. Because of this anatomical alteration, endoscopic retrograde cholangiopancreatography (ERCP) in such a population is significantly challenging.</div><div>Herein we report a case of a 50-year-old woman presented with epigastric and left upper quadrant pain. Preoperative examination revealed abnormal liver chemistries, situs inversus totalis, and multiple distal common bile duct stones with intrahepatic and extrahepatic bile duct dilatation on abdominal ultrasound. The patient underwent a successful ERCP to relieve biliary obstruction. It was performed while the patient was placed in a supine position with the endoscopist standing on the left side of the patient.</div><div>The major emphasis in ERCP is adjusting the patient and endoscopist positions during the procedure. The advantage of the supine position is that the endoscope could easily reach the pyloric ring and, after reaching the duodenum, the papilla could be reached without difficulty.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100555"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11761330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Nonrandomized Pilot Study to Investigate the Acceptability and Feasibility of LivR Well: A Multifaceted 28-Day Home-Based Liver Optimization Program for Acute-on-Chronic Liver Failure","authors":"Natalie L.Y. Ngu ,&nbsp;Edward Saxby ,&nbsp;Thomas Worland ,&nbsp;Patricia Anderson ,&nbsp;Lisa Stothers ,&nbsp;Jo Hunter ,&nbsp;Alexander T. Elford ,&nbsp;Phil Ha ,&nbsp;Imogen Hartley ,&nbsp;Andrew Roberts ,&nbsp;Dean Seah ,&nbsp;George Tambakis ,&nbsp;Declan Connoley ,&nbsp;Anita Figredo ,&nbsp;Dilip Ratnam ,&nbsp;Danny Liew ,&nbsp;Benjamin Rogers ,&nbsp;William Sievert ,&nbsp;Sally Bell ,&nbsp;Suong Le","doi":"10.1016/j.gastha.2024.10.007","DOIUrl":"10.1016/j.gastha.2024.10.007","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Acute-on-chronic liver failure (ACLF) has a 22%–74% 28-day mortality rate and 30%–40% 30-day readmission rate. We investigated the acceptability and feasibility of a multimodal community intervention for ACLF.</div></div><div><h3>Methods</h3><div>A single-arm nonrandomized pilot study of consecutive participants with ACLF was conducted in a tertiary health service. Participants received weekly medical and nursing reviews, dietetics, physiotherapy, pharmacy, social work, addiction medicine, and neuropsychiatry, where indicated. A digital platform included remote weight monitoring and online surveys. The primary outcome was acceptability/feasibility. Secondary outcomes included safety, mortality, readmission, liver disease severity, and costs.</div></div><div><h3>Results</h3><div>Fifty-nine patients were enrolled with median age 51 years (interquartile range (IQR): 45–59); majority alcohol etiology (74%),and median Model for End-Stage Liver Disease Sodium score 16 (IQR: 12–21). LivR Well was acceptable with low attrition (8 of 59), adherence to the program including home visits (mean 8.4 ± 4.2) and consultations (mean 2.4 ± 1.5) per patient. This was supported by positive feedback and themes identified through a qualitative subanalysis. Feasibility was demonstrated by recruitment rate of 4.94 patients/month and 86% completion. Mortality was lower than expected at 3%, 30-day readmission rate was 15%, and median Model for End-Stage Liver Disease Sodium score reduced to 15 (<em>P</em> = .01). Median 6-month costs reduced from $30,454 (IQR: $21,953–$65,657) to $17,657 ($4249–$42,876) (<em>P</em> = .009). The total 6-month health-care cost was $1,868,859 (95% confidence interval 1,081,821–2,655,897) compared to $2,518,227 (95% confidence interval 1,959,610–3,076,844).</div></div><div><h3>Conclusion</h3><div>LivR Well was acceptable, feasible, and safe with low short-term mortality and readmission rates. Health-care costs were reduced by 26% driven by a 40% reduction in 30-day readmission. Further evaluation includes a randomized controlled trial of LivR Well compared to standard care.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100567"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large Language Models Outperform Traditional Natural Language Processing Methods in Extracting Patient-Reported Outcomes in Inflammatory Bowel Disease","authors":"Perseus V. Patel ,&nbsp;Conner Davis ,&nbsp;Amariel Ralbovsky ,&nbsp;Daniel Tinoco ,&nbsp;Christopher Y.K. Williams ,&nbsp;Shadera Slatter ,&nbsp;Behzad Naderalvojoud ,&nbsp;Michael J. Rosen ,&nbsp;Tina Hernandez-Boussard ,&nbsp;Vivek Rudrapatna","doi":"10.1016/j.gastha.2024.10.003","DOIUrl":"10.1016/j.gastha.2024.10.003","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Patient-reported outcomes (PROs) are vital in assessing disease activity and treatment outcomes in inflammatory bowel disease (IBD). However, manual extraction of these PROs from the free-text of clinical notes is burdensome. We aimed to improve data curation from free-text information in the electronic health record, making it more available for research and quality improvement. This study aimed to compare traditional natural language processing (tNLP) and large language models (LLMs) in extracting 3 IBD PROs (abdominal pain, diarrhea, fecal blood) from clinical notes across 2 institutions.</div></div><div><h3>Methods</h3><div>Clinic notes were annotated for each PRO using preset protocols. Models were developed and internally tested at the University of California, San Francisco, and then externally validated at Stanford University. We compared tNLP and LLM-based models on accuracy, sensitivity, specificity, positive, and negative predictive value. In addition, we conducted fairness and error assessments.</div></div><div><h3>Results</h3><div>Interrater reliability between annotators was &gt;90%. On the University of California, San Francisco test set (n = 50), the top-performing tNLP models showcased accuracies of 92% (abdominal pain), 82% (diarrhea) and 80% (fecal blood), comparable to GPT-4, which was 96%, 88%, and 90% accurate, respectively. On external validation at Stanford (n = 250), tNLP models failed to generalize (61%–62% accuracy) while GPT-4 maintained accuracies &gt;90%. Pathways Language Model-2 and Generative Pre-trained Transformer-4 showed similar performance. No biases were detected based on demographics or diagnosis.</div></div><div><h3>Conclusion</h3><div>LLMs are accurate and generalizable methods for extracting PROs. They maintain excellent accuracy across institutions, despite heterogeneity in note templates and authors. Widespread adoption of such tools has the potential to enhance IBD research and patient care.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100563"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Circulating Metabolites Associated With Steatotic Liver Disease and Liver Enzymes: A Multiplatform Population-Based Study","authors":"Yasir J. Abozaid ,&nbsp;Ibrahim Ayada ,&nbsp;Laurens A. van Kleef ,&nbsp;Neil J. Goulding ,&nbsp;Jessica S. Williams-Nguyen ,&nbsp;Robert C. Kaplan ,&nbsp;Robert J. de Knegt ,&nbsp;Lynne E. Wagenknecht ,&nbsp;Nicholette D. Palmer ,&nbsp;Nicholas J. Timpson ,&nbsp;Jill M. Norris ,&nbsp;Yii-Der Ida Chen ,&nbsp;M. Arfan Ikram ,&nbsp;Willem Pieter Brouwer ,&nbsp;Mohsen Ghanbari","doi":"10.1016/j.gastha.2024.09.006","DOIUrl":"10.1016/j.gastha.2024.09.006","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Steatotic liver disease (SLD) is the most common chronic liver disease strongly associated with metabolic dysfunction, but its pathogenesis remains incompletely understood. Exploring plasma circulating metabolites may help in elucidating underlying mechanisms and identifying new biomarkers for SLD.</div></div><div><h3>Methods</h3><div>We examined cross-sectionally the association between plasma metabolites and SLD as well as liver enzymes using data from 4 population-based cohort studies (Rotterdam study, Avon Longitudinal Study of Parents and Children, The Insulin Resistance Atherosclerosis Family Study, and Study of Latinos). Metabolites were assessed in the Nightingale platform (n = 225 metabolites) by nuclear magnetic resonance spectroscopy and in the Metabolon platform (n = 991 metabolites) by ultra-high-performance liquid chromatography-mass spectrometry. Serum levels of liver enzymes (alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transpeptidase) were measured and SLD was diagnosed by ultrasound or computed tomography scan. Logistic and linear regression models were performed per cohort and meta-analyzed. A false discovery rate &lt; 0.05 was considered as significant threshold.</div></div><div><h3>Results</h3><div>Several metabolites were significantly associated with SLD and liver enzymes, of which 21 metabolites were associated with both traits. The most significant associations were observed with phenylalanine, triglycerides in (high-density lipoprotein, intermediate-density lipoprotein, and small low-density lipoprotein), fatty acid (FA) ratios of (18:2 linoleic acid-to-total FA, omega 6 FA-to-total FA, and polyunsaturated FA-to-total FA) from the Nightingale and glutamate and sphingomyelin from the Metabolon platform. Other associated metabolites were mainly involved in lipid, amino acid, carbohydrates, and peptide metabolism.</div></div><div><h3>Conclusion</h3><div>Our study indicates a landscape of circulating metabolites associated with SLD. The identified metabolites may contribute to a better understanding of the metabolic pathways underlying SLD and hold promising for potential biomarkers in early diagnosis and monitoring of the disease.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 2","pages":"Article 100551"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143061559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}